Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

MLA

Makker, V., et al. Updated Efficacy and Safety of Lenvatinib (LEN) plus Pembrolizumab (Pembro) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) with Advanced Endometrial Cancer (AEC): Study 309/KEYNOTE-775. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......9436..1d93a2189a310f4c75144f66c2a25a39&authtype=sso&custid=ns315887.

APA

Makker, V., Colombo, N., Casado Herraez, A., Monk, B. J., Mackay, H., Santin, A. D., & Miller, D. S. (2022). Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775.

Chicago

Makker, V., N. Colombo, A. Casado Herraez, B. J. Monk, H. Mackay, A. D. Santin, and D. S. Miller. 2022. “Updated Efficacy and Safety of Lenvatinib (LEN) plus Pembrolizumab (Pembro) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) with Advanced Endometrial Cancer (AEC): Study 309/KEYNOTE-775,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......9436..1d93a2189a310f4c75144f66c2a25a39&authtype=sso&custid=ns315887.